These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 7752668)
1. The beta 1 hyperselectivity in beta-blocker treatment. Cruickshank JM J Cardiovasc Pharmacol; 1995; 25 Suppl 1():S35-46. PubMed ID: 7752668 [TBL] [Abstract][Full Text] [Related]
2. Beta-blockers and diabetes: the bad guys come good. Cruickshank JM Cardiovasc Drugs Ther; 2002 Sep; 16(5):457-70. PubMed ID: 12652116 [TBL] [Abstract][Full Text] [Related]
3. Beta-blockers in hypertensive and coronary heart disease. Goldstein S Arch Intern Med; 1996 Jun; 156(12):1267-76. PubMed ID: 8651834 [TBL] [Abstract][Full Text] [Related]
4. Beta-blockers and heart failure. Cruickshank JM Indian Heart J; 2010; 62(2):101-10. PubMed ID: 21180298 [TBL] [Abstract][Full Text] [Related]
8. Optimising the use of beta-adrenoceptor antagonists in coronary artery disease. Ellison KE; Gandhi G Drugs; 2005; 65(6):787-97. PubMed ID: 15819591 [TBL] [Abstract][Full Text] [Related]
9. Statin and beta-blocker therapy and the initial presentation of coronary heart disease. Go AS; Iribarren C; Chandra M; Lathon PV; Fortmann SP; Quertermous T; Hlatky MA; Ann Intern Med; 2006 Feb; 144(4):229-38. PubMed ID: 16490908 [TBL] [Abstract][Full Text] [Related]
10. Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy. Bangalore S; Messerli FH; Cohen JD; Bacher PH; Sleight P; Mancia G; Kowey P; Zhou Q; Champion A; Pepine CJ; Am Heart J; 2008 Aug; 156(2):241-7. PubMed ID: 18657652 [TBL] [Abstract][Full Text] [Related]
11. [Beta-blockers for protection against hypertensive target-organ damage]. Takahashi F Nihon Rinsho; 2004 Mar; 62 Suppl 3():583-6. PubMed ID: 15171440 [No Abstract] [Full Text] [Related]
12. Primary and secondary prevention of myocardial infarction and strokes: an update of randomly allocated, controlled trials. Yusuf S; Lessem J; Jha P; Lonn E J Hypertens Suppl; 1993 Jun; 11(4):S61-73. PubMed ID: 8104243 [TBL] [Abstract][Full Text] [Related]
13. The Role of Beta-Blockers in the Treatment of Hypertension. Cruickshank JM Adv Exp Med Biol; 2017; 956():149-166. PubMed ID: 27957711 [TBL] [Abstract][Full Text] [Related]
14. Cardioprotection with beta-adrenoceptor blockers. Does lipophilicity matter? Hjalmarson A Basic Res Cardiol; 2000; 95 Suppl 1():I41-5. PubMed ID: 11192352 [TBL] [Abstract][Full Text] [Related]
15. Choosing the most appropriate treatment for stable angina. Safety considerations. Asirvatham S; Sebastian C; Thadani U Drug Saf; 1998 Jul; 19(1):23-44. PubMed ID: 9673856 [TBL] [Abstract][Full Text] [Related]
16. The role of beta receptor blockade in preventing sudden death. Wikstrand J; Kendall M Eur Heart J; 1992 Sep; 13 Suppl D():111-20. PubMed ID: 1356781 [TBL] [Abstract][Full Text] [Related]
17. Reducing the risk for coronary heart disease and stroke in hypertensives--comments on mechanisms for coronary protection and quality of life. Wikstrand J J Clin Pharm Ther; 1992 Feb; 17(1):9-29. PubMed ID: 1548319 [TBL] [Abstract][Full Text] [Related]
18. Diuretic agents versus beta-blockers. Comparison of effects on mortality, stroke, and coronary events. Furberg CD; Cutler JA Hypertension; 1989 May; 13(5 Suppl):I57-61. PubMed ID: 2577460 [TBL] [Abstract][Full Text] [Related]